TABLE 3.
Parameter Estimates in Model 1 for the Analysis of the Relationship Between Bevacizumab Exposure and the AE Trajectory (n = 510)
| Parameter | AE Trajectory Groupa | Odds Ratio | 95% CI | P |
|---|---|---|---|---|
|
| ||||
| BV exposure | Cardiac Traj | 3.58 | 1.06–12.1 | <.05 |
| Neuro Traj | 1.08 | 0.65–1.80 | .77 | |
| Mixed Reactions Traj | 1.11 | 0.50–2.46 | .79 | |
| Age (10 y) | Cardiac Traj | 1.29 | 0.92–1.82 | .14 |
| Neuro Traj | 1.17 | 0.95–1.44 | .13 | |
| Mixed Reactions Traj | 1.60 | 1.15–2.22 | <.01 | |
| Weight (10 | Cardiac Traj | 1.26 | 1.07–1.49 | <.01 |
| kg) | Neuro Traj | 1.14 | 1.02–1.27 | <.05 |
| Mixed Reactions Traj | 1.17 | 1.00–1.38 | .05 | |
Abbreviations: AE, adverse event; BV, bevacizumab; CI, confidence interval.
a
The Low AE Traj group is the reference group for the odds ratios.